MedTrace Logo

Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease

NCT04620980 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2022-09-28

No results posted yet for this study

Summary

The project intends to assess the polygenic burden of rare disruptive mutations in Parkinson's disease (PD) and how they influence the phenotype/pathological heterogeneity of disease.

Conditions

  • Parkinson Disease

Interventions

DIAGNOSTIC_TEST

targeted resequencing

The investigators will use a disease-specific gene panel including about 100 genes related to Parkinson's Disease, autophagy and levodopa induced Dyskinesia (LID).

Sponsors & Collaborators

  • Neuromed IRCCS

    lead OTHER

Principal Investigators

  • Teresa Esposito, PhD · Head of CNR Unit

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2023-09-30
Completion
2024-05-17

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04620980 on ClinicalTrials.gov